Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance

NCT01295333 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Graves Disease (Basedow's Disease)

Interventions

DRUG: the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation
DRUG: The initiation of LT4 as soon as the first biological signs of hypothyroidism.

Sponsor

Assistance Publique Hopitaux De Marseille